Bendamustine
Based on 6 publication(s) in Google Scholar
Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 16506-27-7
- Formula: C16H21Cl2N3O2
- Molecular Weight:358.26
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Rare Diseases Drug Library
HY-L102
-
Chemotherapy Drug Library
HY-L112
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Bendamustine
More
Customer Validation & Images
-
IF
Biological Activity
DNA Alkylator/Crosslinker[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>92.93 μM
Compound: Bendamustine
|
Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay
|
10.1007/s00044-011-9959-8 |
| HCT-116 | IC50 |
71.69 μM
Compound: Bendamustine
|
Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay
|
10.1007/s00044-011-9959-8 |
| HeLa | IC50 |
>20 μM
Compound: Bendamustine
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
|
[PMID: 33261898] |
| HeLa | IC50 |
>20 μM
Compound: Bendamustine
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 35477142] |
| HeLa | IC50 |
>20 μM
Compound: Bendamustine
|
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation
|
[PMID: 35944852] |
| HL-60 | IC50 |
6.98 μM
Compound: Bendamustine
|
Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay
|
10.1007/s00044-011-9959-8 |
| KB | IC50 |
41.28 μM
Compound: Bendamustine
|
Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay
|
10.1007/s00044-011-9959-8 |
| MDA-MB-231 | IC50 |
13.28 μM
Compound: Bendamustine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
|
[PMID: 33261898] |
| MDA-MB-231 | IC50 |
13.28 μM
Compound: Bendamustine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 35477142] |
| MDA-MB-231 | IC50 |
13.28 μM
Compound: Bendamustine
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation
|
[PMID: 35944852] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
70 μM
Compound: 55
|
Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
|
[PMID: 29870668] |
| Panel NCI-60 (60 carcinoma cell lines) | IC50 |
2.2 μM
Compound: 35; CY190602
|
Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition
Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition
|
[PMID: 33143937] |
| Panel NCI-60 (60 carcinoma cell lines) | IC50 |
77 nM
Compound: 161
|
Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines)
Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines)
|
[PMID: 33077264] |
| Panel NCI-60 cells | GI50 |
70 μM
Compound: 55
|
Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
|
[PMID: 29870668] |
Bendamustine is a DNA cross-linking agent that causes DNA breaks, with alkylating and antimetabolite properties. Bendamustine uniquely regulates apoptosis pathways and DNA repair pathways in non-Hodgkin's lymphoma cells. Bendamustine (50 μM) induces p21 (Cip1/Waf1) and NOXA genes, and increases the expression of p53 in SU-DHL-1 cells. Bendamustine (25 μM) blocks mitotic checkpoints and cuases mitotic catastrophe[1].
Bendamustine reduces the viability of multiple myeloma (MM) cell lines, such as RPMI-8226 and 8226-LR5 cells, with IC25s of 101.8 μM and 585.5 μM after 24 h incubation, and 51.7 and 374.3 μM after 48 h incubation, respectively. Bendamustine induces a specific caspase-dependent MM cell death and inhibits the spindle-assembly checkpoint[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 16506-27-7
-
Appearance Solid
-
Molecular Weight 358.26
-
Formula C16H21Cl2N3O2
-
Color White to off-white
-
SMILES
O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
-
Synonyms
SDX-105 free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Leukemia
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. [Abstract]2023 Nov;37(11):2221-2230. PMID: 37752286 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Bendamustine purchased from MedChemExpress. Usage Cited in: J Biomed Res. 2017 0(0): 1-12.
Testis cross-sections are stained with anti-PLZF antibody (red), and Hoechst 33342 (blue). Higher magnification images showing localization of PLZF-positive spermatogonia stem cells at the base of the seminiferous epithelium in contact with the basal membrane (arrows indicate PLZF+cells). A, B: sections from the testis of Bendamustine (BD) control mice and BD treated mice.
-
Solvent & Solubility
DMSO : 100 mg/mL (279.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cytotoxicity of both Bendamustine and melphalan on multiple myeloma (MM) cells is calculated as inhibition of cell viability by measuring the percentage of cell survival by MTS assay. Briefly, cells (1 × 104/well) are seeded in 96-well plates with increasing concentrations of the drug and analyzed after 24, 48, 72 and 96 h of incubation. To this end, 1 μg/mL of MTS solution is added to each well and, after 1 h at 37 °C, the dark blue formazan crystals are dissolved by isopropanol 1 N and HCl (24:1, vol/vol). Finally, the absorbance is measured at 490 nm in a 96-well plate reader. Cell survival is estimated as the percentage of the absorbance of untreated controls and each test is performed in triplicate. The inhibitory concentrations 50 (IC50) and 25 (IC25) of each drug, being the amount able to reduce cell growth to 50% and 25%, respectively, of that of untreated control cells, are calculated, and the tests are performed in parallel using equitoxic concentrations of Bendamustine and melphalan. The relative resistance index (RRI) is expressed as the ratio of the IC50 of 8226-LR5 to the IC50 of RPMI-8226 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
C.B.-17 scid mice (DoHH-2, Granta 519) or C.B.-17 scid-bg mice (SuDHL-4, RAMOS) are inoculated with 1 × 106 (DoHH-2, RAMOS), 3 × 106 (SuDHL-4) or 5 × 106 (Granta 519) cells s.c. in the right flank. For flank xenografts, inoculation volume is 0.2 mL consisting of a 50:50 mixture of cells in growth medium and Matrigel. Tumour volume is estimated by two to three weekly measurements of the length and width of the tumour by electronic calipers and applying the following equation: V=L×W2/2. Tumours are allowed to reach approximately 250 mm3, and mice are size-matched (day 0) into treatment and control groups. For systemic Granta 519 tumour models, 2 × 106 cells are injected via the tail vein in 0.1 mL volume of cell medium on day 0, and treatment is initiated on day 14. All animals are ear-tagged and monitored individually throughout the experiment. Navitoclax is administered by oral gavage once daily in a mixture of Phosal 50PG : PEG400 : ethanol. Bendamustine and rituximab are administered i.v. at 25 mg/kg and 10 mg/kg, respectively, on day 1. Navitoclax is administered approximately 2 h before Bendamustine and rituximab. All trials are comprised of 10 mice per group. Mice are humanely killed when tumours reach a size >2000 mm3 or when any signs of distress are monitored. Signs of distress include loss of ambulation, laboured breathing or weight loss > 20% mean body weight per cage[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. [Content Brief]
[2]. Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17. [Content Brief]
[3]. Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7913 mL | 13.9563 mL | 27.9127 mL | 69.7817 mL |
| 5 mM | 0.5583 mL | 2.7913 mL | 5.5825 mL | 13.9563 mL | |
| 10 mM | 0.2791 mL | 1.3956 mL | 2.7913 mL | 6.9782 mL | |
| 15 mM | 0.1861 mL | 0.9304 mL | 1.8608 mL | 4.6521 mL | |
| 20 mM | 0.1396 mL | 0.6978 mL | 1.3956 mL | 3.4891 mL | |
| 25 mM | 0.1117 mL | 0.5583 mL | 1.1165 mL | 2.7913 mL | |
| 30 mM | 0.0930 mL | 0.4652 mL | 0.9304 mL | 2.3261 mL | |
| 40 mM | 0.0698 mL | 0.3489 mL | 0.6978 mL | 1.7445 mL | |
| 50 mM | 0.0558 mL | 0.2791 mL | 0.5583 mL | 1.3956 mL | |
| 60 mM | 0.0465 mL | 0.2326 mL | 0.4652 mL | 1.1630 mL | |
| 80 mM | 0.0349 mL | 0.1745 mL | 0.3489 mL | 0.8723 mL | |
| 100 mM | 0.0279 mL | 0.1396 mL | 0.2791 mL | 0.6978 mL |
Bendamustine Related Classifications
HY-13567 Related Classifications
Powered by Bioz